Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on May 27, 2025
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon
GlobeNewswire
·
May 27, 2025
27 mai 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que son partenaire exclusif au Japon pour NCX …
Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease
GlobeNewswire
·
May 27, 2025
AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on developing new therapies for …
Press Release: Sanofi completes acquisition of DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition …
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société biopharmaceutique privée au stade …
Press release: Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders
GlobeNewswire
·
May 27, 2025
Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders Continued strong support from major shareholders alfapump® US commercial launch remains on track for Q3 2025 through specialty …